Dr. Tyler Cassidy
Identifying determinants of long-term viral suppression following broadly neutralizing antibody treatment against HIV-1
January 7, 2025
Room 102: Lecture Theatre - Michael Smith Laboratories
Due to their long circulating half-life, high neutralization potency, and large breadth of coverage, broadly neutralizing antibodies are increasingly studied for the treatment of HIV-1 infection. Recent phase I clinical studies of antibody treatment have demonstrated robust and durable antiviral... Read more